Cobimetinib (GDC-0973, RG7420) is a potent and highly selective MEK1 inhibitor with IC50 of 4.2 nM, and showing no significant inhibition when tested against a panel of more than 100 of serine-threonine and tyrosine kinases. Cobimetinib induces apoptosis. Phase 3.
Statement:
->>Products covered by valid patents are not offered or supplied for commercial use.
->>Products currently covered by valid US Patents are offered for laboratory R&D use in accordance with 35 USC 271(e)+A13(1).
->>Any patent infringement and resulting liability is solely at buyer's risk.
->>Our products are only raw materials for drugs or industry, can't be used for human or animals directly.